Roles of fluoxetine and haloperidol in mouse models of DOI-induced head twitch response

Chinese Journal of Contemporary Pediatrics

Volumn 9, Issue 5, 2007, Pages 469-472

  Yao, Yang ^a   Ma, Hong Wei ^a   Lu, Yao ^a   Dai, Xiao Mei ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

DOI; Fluoxetine; Haloperidol; Mice; Tourette syndrome

Indexed keywords

4 IODO 2,5 DIMETHOXYAMPHETAMINE; DOPAMINE; FLUOXETINE; HALOPERIDOL; HOMOVANILLIC ACID; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE SIMULATION; DRUG MECHANISM; DRUG RESPONSE; GILLES DE LA TOURETTE SYNDROME; HEAD TWITCH; MONOTHERAPY; MOUSE; NEUROCHEMISTRY; NONHUMAN;

AMPHETAMINES; ANIMALS; DISEASE MODELS, ANIMAL; DOPAMINE; FLUOXETINE; HALOPERIDOL; HOMOVANILLIC ACID; MALE; MICE; RECEPTOR, SEROTONIN, 5-HT1A; TOURETTE SYNDROME;

EID: 35348945756     PISSN: 10088830     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Rampello L, Alvano A, Battaglia G, Bruno V, Raffaele R, Nicoletti F. Tic disorders: from pathophysiology to treatment[J]. J Neurol, 2006, 253(1): 1-15.
2. Hayslett RL, Tizabi Y. Effects of donepezil on DOI-induced head twitch response in mice: implications for Tourette syndrome [J]. Pharmacol Biochem Behav, 2003, 76(3-4): 409-415.
3. Tizabi Y, Russell LT, Johnson M, Darmani NA. Nicotine attenuates DOI-induced head-twitch response in mice: implications for Tourette syndrome[J]. Prog Neuro-Psychopharmacol Biol Psychiat, 2001, 25(6):1445-1457.
4. Eapen V, Trimble MR, Robertson MM. The use of fluoxetine in Gilles de La Tourette syndrome and obsessive compulsive behaviours: preliminary clinical experience [J]. Prog Neuropsychopharmacol Biol Psychiatry, 1996, 20(4): 737-743.
5. Scahill L, Riddle MA, King RA, Hardin MT, Rasmusson A, Makuch RW, et al. Fluoxetine has no marked effect on tic symptoms in patients with Tourette's syndrome: a double-blind placebo-controlled study [J]. J Child Adolesc Psychopharmacol, 1997, 7 (2): 75-85.
6. Silvestri R, Raffaele M, De Domenico P, Tisano A, Lagana A, Di Perri R. Serotoninergic agents in the treatment of Gilles de la Tourette's syndrome [J]. Acta Neurol (Napoli), 1994, 16(1-2):58-63.
7. Kurlan R, Como PG, Deeley C, McDermott M, McDermott MP. A pilot controlled study of fluoxetine for obsessive-compulsive symptoms in children with Tourette's syndrome [J]. Clin Neuropharmacol, 1993, 16(2):167-172.
8. Minzer K, Lee O, Hong JJ, Singer HS. Increased prefrontal D2 protein in Tourette syndrome: a postmortem analysis of frontal cortex and striatum[J]. J Neurol Sci, 2004, 219(1-2):55-61.
9. Albin RL, Koeppe RA, Bohnen NI, Nichols TE, Meyer P, Wernette K, et al. Increased ventral striatal monoaminergic innervation in Tourette syndrome[J]. Neurology, 2003, 61(3):310-315.
10. Sallee FR, Gilbert DL, Vinks AA, Miceli JJ, Robarge L, Wilner K. Pharmacodynamics of ziprasidone in children and adolescents: impact on dopamine transmission [J]. J Am Acad Child Adolesc Psychiatry, 2003, 42(8): 902-907.
11. Muller-Vahl KR, Meyer GJ, Knapp WH, Emrich HM, Gielow P, Brucke T, et al. Serotonin transporter binding in Tourette syndrome[J]. Neurosci Lett, 2005, 385(2):120-125.
12. Chinese source.